The Future of Weight Loss Drugs (October 2026)

01 · The core answer

What is the future of weight loss drugs?

The future of weight loss drugs is a wider toolbox. Today, the licensed options in the UK include injectable medicines taken weekly or daily, and now some tablets. Next come further combinations that act on more than one hormone pathway, and attempts to improve what people lose (fat rather than muscle) and how well they keep it off. Each of these is at a different stage, and honesty about that stage matters more than excitement.

The pattern is clear. The headline promise of any new drug is not reliable until it is licensed, studied in large trials and reviewed by regulators. Until then, the useful question is not "what will exist in future?" but "what is the right regulated treatment for me now?"

02 · Your decision

Should you wait for newer drugs?

Waiting is rarely the right default if you already meet the licensed criteria. Medicines in research may never reach UK pharmacies, may arrive later than hoped, or may suit different people. Meanwhile, current licensed treatments exist, have large trials behind them and come with a monitoring framework.

In the SURMOUNT-1 trial of 2,539 adults, people taking tirzepatide alongside diet and exercise lost on average 15% of their body weight on 5mg, 19.5% on 10mg and 20.9% on 15mg over 72 weeks, compared with 3.1% with lifestyle changes alone.² These are trial averages — individual results vary, and treatment works alongside a reduced-calorie diet and increased physical activity, not instead of them.²

That does not mean Mounjaro is right for everyone. Some people prefer a tablet, some cannot tolerate injectable medicines, and some will qualify for NHS treatment sooner than they expect. A prescriber can help you weigh these points. Our weight loss clinic explains how the consultation works, and our guide to weight loss drugs compares the licensed options side by side.

03 · A sensible filter

How to read future-of-obesity-drug headlines

Four questions cut through most announcements. Is the medicine licensed in the UK? Has it been studied in a large trial that has been published and peer reviewed? Is it compared with a proper control, or is it a small early study? And does the claim describe an average, or does it imply that you will get the same result? Averages in trials describe groups; they do not predict your own result.

Applying these filters, many of the "next big thing" stories are really early research. That is not a criticism of the science. It simply means the right response today is curiosity, not a purchase decision.

If you are ready to explore treatment now, the next step is a free online consultation, reviewed by a GPhC-registered prescriber. The Mounjaro 2.5mg pen has a standard price of £169.99, and all six doses are in stock.

04 · Where treatment stands now

Where weight loss treatment stands today

To judge the future, start with the present. Mounjaro is the brand name for tirzepatide, a once-weekly injectable prescription medicine made by Eli Lilly. In the UK it is licensed for weight management in adults and for type 2 diabetes. It comes as a pre-filled multi-dose pen (KwikPen) in six strengths: 2.5mg, 5mg, 7.5mg, 10mg, 12.5mg and 15mg.¹

Tirzepatide is the first treatment of its kind to activate two natural gut-hormone receptors at once: GIP and GLP-1. Together these help regulate appetite, slow how quickly the stomach empties, and improve the way the body responds to insulin.¹ In practice, most people feel fuller sooner and less hungry between meals, which supports a reduced-calorie diet.¹

This dual action is what distinguishes Mounjaro from single-action medicines such as semaglutide (Wegovy and Ozempic).¹ Much of the research you read about in headlines is an attempt to go further down that road: more hormone pathways, or the same pathways delivered more conveniently.

In the SURMOUNT-1 trial of 2,539 adults, people taking tirzepatide alongside diet and exercise lost on average 15% of their body weight on 5mg, 19.5% on 10mg and 20.9% on 15mg over 72 weeks, compared with 3.1% with lifestyle changes alone.² At 72 weeks, 85% of participants on 5mg, 89% on 10mg and 91% on 15mg had lost at least 5% of their body weight.² Those are trial averages and individual results vary.

Any new medicine has to show, in a large, well-run trial, that it does something clearly useful compared with what already exists: more weight lost, better tolerability, easier use, lower cost, or a benefit for a group that current treatments serve less well. Until a medicine shows that, it is a promise rather than a treatment.

One more point about the present. A prescription medicine is not just a product; it is a package of assessment, dosing, review and follow-up. Treatment is used alongside a reduced-calorie diet and increased physical activity. That structure is unlikely to disappear however the drugs themselves change.

So when someone asks what the future looks like, the honest summary is that the present is already substantial. The next steps are refinements and additions, not a replacement of everything that exists today. Anyone who needs support with their weight should not feel they are choosing between today's medicine and tomorrow's: for most people, the realistic choice is between acting with proper medical guidance now and delaying while the research matures.

05 · Tablets and oral options

Tablets instead of injections: the clearest shift

The most visible change in weight loss medicine is the move from pens to pills. Many people are comfortable with a weekly pen, but others dislike needles, worry about storage, or would simply prefer something they can take with a glass of water. Tablets answer that preference, and they are the part of the "future" story that has already begun to arrive in the UK.

Two tablet products carry published UK product information: Wegovy tablets (oral semaglutide) and Foundayo (orforglipron). See the current details on our product pages, including the Wegovy pen page for the injectable version of semaglutide and the tablet listings where they are offered.

Tablets change some things and not others. They change the route: a daily tablet instead of an injection. They do not change the principle that treatment is prescription-only, assessed by a prescriber, and used alongside a reduced-calorie diet and increased physical activity. They do not remove the need to think about side effects, and they do not turn a medicine into an over-the-counter product.

There is also a practical difference worth understanding: frequency. For comparison, liraglutide (Saxenda, and products such as Erly) is a daily injection supplied at a concentration of 6mg per millilitre, unlike once-weekly Mounjaro and Wegovy. Daily regimens ask more of you than weekly ones, whether the daily item is an injection or a tablet. Some people value the routine, others find it a burden. Neither preference is wrong.

Why do so many people expect tablets to cost less? Manufacturing a tablet can be simpler than filling and assembling a pen, and that is where the hope for lower prices comes from. Whether that translates into lower prices in a UK pharmacy depends on the manufacturer, the licence and the market. Mounjaro prices across the UK pharmacies we track currently range from £143.96 to £339.00 per month depending on dose and provider (checked 10 October 2026); tablet prices are best checked live on the product page.

The sensible approach for a reader today is simple. If you want a tablet, ask during your consultation whether it is appropriate for you. Either way, a prescriber should make the decision with you, based on your health, your other medicines and your preferences, not on which format is newest.

Finally, remember that format is only one dimension. A tablet that does not suit you, or that you stop taking because of side effects, helps less than a pen you can continue. The format that suits you is the one you can use safely over time, under review.

06 · Next-generation research

New combinations and drugs in research

Beyond tablets, the research pipeline is where most of the excitement lies. Names such as retatrutide and bimagrumab appear in headlines, usually attached to promises of larger weight loss or better preservation of muscle.

The success of medicines that act on gut-hormone receptors has led researchers to ask whether adding more pathways could do more. Mounjaro itself was an example of that thinking: it activates two receptors, GIP and GLP-1, rather than one.¹ Newer candidates extend the idea, combining more targets in a single medicine or pairing a weight-loss drug with a different type of drug.

Do not mistake research interest for proven benefit. Several things must go right before a medicine becomes a treatment you can ask your prescriber about:

• Large, well-controlled trials must show a meaningful benefit over existing treatment or placebo.
• Safety has to be studied over a long enough period, including in people with other conditions and medicines.
• Regulators must review the evidence and grant a licence, and the product must be approved for use in the UK specifically.
• It must then be manufactured, distributed and priced in a way that makes it accessible.

Any of these stages can slow a promising medicine or stop it. That is normal, and it is the reason we advise caution with phrases like "coming soon". Without a licence, a UK pharmacy cannot lawfully supply a medicine for weight loss, and anyone offering an unlicensed product of this kind should be treated with great suspicion.

This is also where counterfeit and unregulated sellers thrive. When a new drug generates headlines, some sellers advertise it before it is available, often as "research chemicals" or powders. The MHRA publishes counterfeit medicine alerts and runs the Yellow Card scheme for reporting problems.⁷ A regulated UK pharmacy supplies licensed medicines only after a consultation and a prescription. Anyone offering to supply without a consultation or prescription is not operating within the rules, whatever the product is called.

The helpful stance is open-minded and practical. Follow the research with interest, expect it to take years, and make today's decisions with the medicines you can actually obtain. If a new treatment reaches the UK with a licence and strong evidence, our prescribing team will assess it like any other. Our piece on the wider future of these drugs follows the same pipeline in more detail, and the guide on how to invest in weight loss drugs covers the commercial side for readers who come at this as investors rather than patients.

07 · Muscle, maintenance, stopping

Muscle, maintenance and what happens after treatment

Two questions dominate future-of-treatment discussions among people who already use these medicines. How do you protect muscle while losing weight? And what happens when treatment stops? Both matter, and both are areas where honesty beats optimism.

On muscle, research is active, and the idea of pairing a fat-reducing medicine with something that helps keep lean tissue is genuinely interesting. Talk to your prescriber or a dietitian about protein and resistance-type movement.

On stopping, there is a firm factual point about the drug itself. Tirzepatide has a half-life of about five days, so after a final dose it takes roughly four to five weeks to clear the system, there is no way to speed this up, and nothing needs doing while it clears.¹ That tells you about the medicine leaving the body. It does not tell you what will happen to your appetite or weight afterwards. In SURMOUNT-4, people who stopped tirzepatide after 36 weeks regained on average 14% of body weight over the following year, while those who continued treatment lost a further 5.5% on average. Stopping should always be planned with your prescriber, with diet and activity habits ready to carry the load.¹⁴

Why do people stop at all? Reasons vary: side effects, cost, reaching a goal, a change in health, or simply a wish to stop. Each person's situation is different, so the sensible route is to talk it through with the prescriber who reviews your treatment. Our ongoing monthly reviews, dose-titration and follow-up assessments are there for exactly this reason, and repeat orders re-check suitability, with no auto-shipping.

Looking ahead, much of the field's attention is on maintenance: how to keep a lower weight over time. Today, the licensed dose range for Mounjaro is the set of six strengths from 2.5mg to 15mg, and changes to dose are made by a prescriber, not by the patient.

One more element of the future is likely to be better tracking. Keeping a record of doses, side effects and weight over time makes reviews more useful. Our free companion app, GLPTrackr (iOS and Android), is built for tracking a journey of this kind.

In short: the future may bring clever ways to protect muscle and maintain results, but the habits that matter most are available today. Eat in a way you can sustain, stay physically active, attend your reviews and keep your prescriber informed. Those habits will remain relevant whatever medicines come next.

08 · NHS and private care

The NHS, access and the private option

A major part of the future of weight loss drugs is who gets them and how. For the NHS, that story is already moving. Mounjaro is available on the NHS, but access is being phased in over several years.⁴ NICE recommends it for adults with a BMI of at least 35 plus at least one weight-related condition, and the NHS primary-care rollout began in June 2025 with the highest-need groups first (initially BMI 40+ with four or more qualifying conditions).⁶ Full rollout is expected to take years, which is why many people who meet the licensed criteria choose regulated private treatment rather than waiting.⁶

Put simply, the direction of travel is towards wider NHS access, but the pace is gradual. If you think you may qualify, speak to your GP and read the NHS guidance on tirzepatide.⁵ NHS access to Wegovy runs through specialist weight-management services; ask your GP.

Why does the pace matter to your decision? Because the choice is rarely "NHS or private forever". For some people, NHS treatment will be available in a reasonable time and the right route. For others, the wait is long, or their circumstances do not match the current criteria. Private treatment is a bridge for some and a long-term choice for others. Neither is a moral decision; both should come with the same clinical oversight.

What should regulated private treatment look like? At EverydayMeds, a GPhC-registered UK online pharmacy (registration 9012878), the process is straightforward:

• You complete a free online consultation, a short health questionnaire with no charge and no obligation.
• A GPhC-registered prescriber reviews it, not a scoring script. Payment is taken when you place the order; if the prescriber decides the treatment is not suitable, the order is refunded automatically in full.
• Our registered pharmacy dispenses, with same-day dispatch when ordered by 3pm.
• Delivery is free next-day tracked (DPD, temperature-controlled packaging, discreet). Saturday delivery is £14.99.

Mounjaro comes through official LillyDirect supply, directly from Eli Lilly's UK distribution, as genuine KwikPens. If you are comparing providers or want a pharmacy-level overview, our page on a weight loss drugs pharmacy explains what to look for.

The future will likely bring more of the same tension: demand that exceeds NHS capacity, more products, and more people asking where to turn. A sensible reader keeps a few principles. Check the pharmacy on the GPhC register. Expect a real consultation. Expect ongoing reviews. And keep your GP informed about what you take, because your wider care benefits from the full picture.

If you meet the criteria for NHS care and can access it, that is one route. If you cannot, or prefer not to wait, regulated private treatment with proper review is a legitimate alternative, and it is available now rather than at some uncertain point in the rollout.

09 · Cost and access ahead

Will weight loss drugs get cheaper and easier to get?

Everyone wants to know whether these medicines will become cheaper.

Forces that could lower costs include more competition between manufacturers, tablet formulations that are simpler to produce, wider NHS purchasing, and a market that has matured after the early surge in demand. Forces that could keep prices high include manufacturer pricing decisions, licence terms and continuing demand. In 2025, Eli Lilly announced a list-price increase for Mounjaro in the UK, so prices do not only move in one direction.¹⁰

What does the current picture look like? Across the UK pharmacies we track, Mounjaro pens range from £143.96 to £339.00 per month depending on dose and provider (checked 10 October 2026). The 2.5mg starting pen alone ranges from £143.96 to £179.99. The gap between providers for the same dose can be as small as £27 or as large as £41. Those are real differences, so compare like with like when you shop around.

Our own standard prices are shown live. The Mounjaro pen starts at £169.99 for the 2.5mg strength, and the full set of six doses is in stock. New customers save £40 on their first order with code FIRST40, and an automatic £25 reorder discount applies to every future order (code DOSE25). The consultation is free, the price shown is the price paid, and there are no subscriptions. Klarna and pay-monthly options are available.

For planning, think in terms of the course, not just the pen. If you step up after 4 weeks on each dose, your first four pens (2.5mg to 10mg) cost £959.96 at standard prices. A first year (13 pens) costs £2,711.88 if you stay on 5mg after your 2.5mg starting pen, up to £3,599.88 if you step up through every dose to 15mg. A new customer's first order is £40 less, and every later order £25 less. These totals will help you budget, whatever changes come to the market later.

What about access? Beyond price, access depends on supply, regulation and your own suitability. Official supply routes matter: buying from sources that are not regulated carries real risks, including counterfeit products. Sticking with a pharmacy on the GPhC register and a medicine supplied through proper channels is the simplest protection.

If you are weighing up the economics of the whole sector rather than your own treatment, that is a different question, covered in our guide on how to invest in weight loss drugs. For personal decisions, the practical rule is this: do not delay effective, supervised treatment in the hope of a price drop that may not arrive on any predictable schedule.

10 · Hype versus evidence

Hype, supplements and what safety looks like

As interest in weight loss drugs has grown, so has marketing that borrows their reputation. Phrases such as "poor man's Ozempic" and "nature's Ozempic" are applied to low-cost supplements like berberine. These are available cheaply without assessment, dosing is not standardised, and they come with no clinical oversight. Marketing may suggest dramatic weight-loss claims, but a supplement is not a licensed medicine and should not be treated as an equivalent.

The same caution applies to older, stimulant-type drugs sometimes discussed in this space. If you are curious about how those fit into the story, our related piece on amphetamine drugs for weight loss explains why they are a different category from today's licensed medicines.

What does a safe future look like? Several principles are unlikely to change:

• Prescription-only supply. Mounjaro (tirzepatide) is a prescription-only medicine, supplied only after an online consultation reviewed by a GPhC-registered prescriber.
• Ongoing review. A prescriber should check how you are tolerating treatment and whether it is still right for you.
• Honest expectations. Individual results vary, and trial averages do not predict your own result.
• Reporting. If you experience a side effect, report it through the MHRA Yellow Card scheme as well as telling your prescriber.¹⁹
• Genuine supply. The MHRA publishes counterfeit medicine alerts, and genuine products come from regulated pharmacies.⁷

If a symptom is not on the UK patient leaflet list, it is not a listed side effect; tell your prescriber about any new or lasting symptom. The patient information leaflet and the SmPC are the right places to check what is listed for a medicine you are considering.

Finally, consider how you hear about the future. Social media threads, forum posts and aggregated summaries often blend facts, opinion and speculation in a single paragraph. A useful habit is to ask where each claim comes from and whether it names a published study and a licensed product. If it does not, set it aside. Our reviews of weight loss drugs take that approach, and the page on tamoxifen and weight loss drugs shows how interactions with other medicines are a prescriber conversation, not a forum question.

11 · Serious side effects

Serious side effects: when to get help straight away

Serious side effects are uncommon but need urgent attention. Seek immediate medical help for: severe, persistent stomach pain that may spread to your back, with or without vomiting (possible pancreatitis); pain in the upper right abdomen, fever or yellowing of skin/eyes (possible gallbladder problems); or signs of a severe allergic reaction such as swelling of the face or throat and difficulty breathing. If you take insulin or a sulfonylurea alongside Mounjaro, watch for low blood sugar (shakiness, sweating, confusion) — your prescriber may need to adjust those medicines.¹